Tenax Therapeutics, Inc. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
TNX-103The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.	Insuffisance cardiaque	Phase 3	À vérifier	United States, Argentina, Austria, Brazil, Bulgaria, Czechia, France, Germany, …	À vérifier
TNX-103The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.	Insuffisance cardiaque	Phase 3	À vérifier	United States, Argentina, Austria, Brazil, Bulgaria, Czechia, France, Germany, Hungary, Italy, Poland, South Korea, Spain, Taiwan, United Kingdom	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
TNX-103	Insuffisance cardiaque	Phase 3	NCT07288398	LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.